Summary of CeriBell FY Conference Call (December 03, 2025) Company Overview - CeriBell has developed a novel neuro monitoring platform that simplifies EEG acquisition, allowing non-specialized personnel to set it up quickly [3][4] - The platform includes a strong AI algorithm named Clarity, which focuses on seizure detection in acute care settings [3][4] Industry and Market Insights - The total addressable market (TAM) for seizure detection in the U.S. is estimated at over $2 billion [4] - CeriBell is currently active in over 600 accounts in the U.S., achieving $22.6 million in revenue for the last quarter, representing a 31% year-over-year growth [5] Clinical Unmet Needs - Seizures in ICU settings are often non-convulsive and can last for hours or days, leading to high mortality and morbidity rates [8][9] - Approximately 33% of neuro ICU patients experience seizures, with a significant portion being non-convulsive [9][10] - Early detection and treatment of seizures are critical, as treating within the first 30 minutes can lead to an 80% success rate [12] Product and Technology - CeriBell's system allows for rapid EEG setup and continuous monitoring, which is crucial for timely intervention [19][20] - The AI algorithm Clarity analyzes EEG data every ten seconds to detect seizures and provides real-time alerts [22][23] - The device is designed for ease of use, enabling nurses and residents to set it up in minutes [19] Clinical Evidence and Outcomes - CeriBell has published over 45 peer-reviewed journals demonstrating the effectiveness of its device [29] - The SAFR trial showed a reduction in ICU length of stay by 4.1 days and an 18% improvement in clinical outcomes [30][31] Business Model - Revenue is derived from a subscription model (25%) and sales of disposable headbands (75%) [32] - CeriBell has maintained consistent quarter-over-quarter growth since its inception, indicating a strong business model [34] Growth Strategy - The company aims to penetrate the U.S. market further, currently at only 3% penetration [35] - Future growth horizons include expanding EEG applications beyond seizure management and into other neurological conditions [36][39] - CeriBell has achieved FedRAMP high cybersecurity certification, allowing access to VA hospitals and expanding its market reach [40][41] Conclusion - CeriBell is positioned as a leader in the neuro monitoring space with a validated commercial model and significant growth potential across multiple indications [42]

Summary of CeriBell (CBLL) FY Conference - June 03, 2025 Company Overview - CeriBell is focused on developing an AI-driven neural monitoring platform for seizure detection in acute care settings, specifically in ICUs and emergency departments [2][5] - The company has a total addressable market (TAM) of over $2 billion in the U.S. for seizure detection alone [5] Core Product and Technology - CeriBell's platform includes hardware and an AI-powered seizure detection algorithm, allowing for rapid EEG setup and monitoring [4][23] - The AI algorithm, named Clarity, continuously monitors EEG signals and alerts medical staff in real-time about seizure activity [23][24] - The system can set up EEG in minutes, contrasting with traditional methods that can take hours or days [23][25] Clinical Need and Impact - Seizures in ICU patients often go unnoticed due to the lack of symptoms, leading to high mortality rates if not detected early [7][11] - Early detection is critical; mortality rates increase significantly with delays in treatment [12][11] - CeriBell's technology addresses the bottlenecks of traditional EEG monitoring, which requires specialized technicians and can lead to delays in patient care [15][17] Commercial Performance - CeriBell reported $20.5 million in revenue last quarter, representing a 42% year-over-year growth [5] - The company is currently trending towards 600 hospitals, with a gross margin of 88% [5] - The revenue model consists of 25% from AI subscription fees and 75% from disposable headband sales [40][41] Market Expansion and Future Pipeline - CeriBell has expanded its TAM by qualifying for cloud-based operations in VA facilities and gaining FDA clearance for pediatric applications [49][50] - Future plans include submitting applications for neonate clarity and using EEG for other indications like delirium and stroke [58] Health Economics and Clinical Evidence - CeriBell's technology has shown to reduce unnecessary patient transfers by 94-100% and decrease length of stay in hospitals by an average of 4.1 days [36][37] - The company qualifies for existing EEG CPT codes, enhancing hospital reimbursement opportunities [38] - CeriBell has published over 35 peer-reviewed journals, demonstrating strong clinical evidence for its impact [39] Sales and Marketing Strategy - The sales force is divided into territory managers for account acquisition and clinical account managers for existing accounts [42] - The business model is characterized by high customer retention and consistent usage, making it difficult for competitors to lure away clients [44][46] Conclusion - CeriBell's innovative approach to seizure detection in acute care settings has the potential to significantly improve patient outcomes while also providing economic benefits to hospitals [60] - The company is well-positioned for future growth with a strong focus on expanding its technology and market reach [60]